The impact of stigmatization of psoriasis, atopic dermatitis and mastocytosis in different areas of life-A qualitative interview study.

Autor: Heim-Ohmayer P; Department of Sport and Health Sciences Technical University of Munich Munich Germany., Freiberger A; Department of Sport and Health Sciences Technical University of Munich Munich Germany., Gedik M; Department of Sport and Health Sciences Technical University of Munich Munich Germany., Beckmann J; Department of Sport and Health Sciences Technical University of Munich Munich Germany.; School of Human Movement and Nutrition Sciences The University of Queensland Brisbane Queensland Australia., Ziehfreund S; Department of Dermatology and Allergy School of Medicine Technical University of Munich Munich Germany., Zink A; Department of Dermatology and Allergy School of Medicine Technical University of Munich Munich Germany.; Unit of Dermatology and Venereology Department of Medicine Karolinska University Hospital Karolinska Institutet Solna Sweden., Hähl W; Department of Sport and Health Sciences Technical University of Munich Munich Germany., Schielein MC; Department of Dermatology and Allergy School of Medicine Technical University of Munich Munich Germany.; Unit of Dermatology and Venereology Department of Medicine Karolinska University Hospital Karolinska Institutet Solna Sweden.
Jazyk: angličtina
Zdroj: Skin health and disease [Skin Health Dis] 2021 Jul 29; Vol. 2 (4), pp. e62. Date of Electronic Publication: 2021 Jul 29 (Print Publication: 2022).
DOI: 10.1002/ski2.62
Abstrakt: Background: Stereotypes and false assumptions about chronic and visible skin diseases can determine the behaviour towards affected individuals and result in stigmatization or discrimination.
Objective: The aim of this study was to analyze the perceived disease-related stigmatization of individuals with psoriasis, atopic dermatitis (AD) or mastocytosis. The study also aims to broaden people-centred knowledge of the effects of stigmatization in different areas of life, namely in everyday life, at work, in sports and in relationships.
Methods: Qualitative in-depth semi-structured interviews were conducted among individuals with either psoriasis, AD or mastocytosis. Participants were recruited via self-help networks and were asked to express their experience of stigmatization in different areas of life. All interviews were audio recorded, transcribed verbatim and evaluated based on Mayring's content analysis.
Results: In total, 24 individuals aged 19-79 years and living in Germany were included in the study-eight for each disease. Stigmatization was experienced in all three diseases in all mentioned areas of life as well as in interaction with medical professionals. Self-exclusion, negative self-perception and negative behaviour of others were the most frequent experiences with stigmatization.
Conclusion: Stigmatization, both internal and external, is an important factor contributing to the mental burden of people with chronic skin diseases. More research is needed to gain deeper insight into stigmatization and its psychological burden in various contexts to enhance people-centred care in chronic skin diseases.
Competing Interests: S. Ziehfreund has received speaker honoraria and travel fees from Novartis. M. C. Schielein has been an advisor and/or received speaker's honoraria of the following companies: Beiersdorf, Janssen‐Cilag, Leo Pharma, Novartis. A. Zink has been an advisor and/or received speaker's honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Almirall, Amgen, Beiersdorf Dermo Medical, Celgene, Eli Lilly, GSK, Janssen Cilag, Leo Pharma, Miltenyi Biotec, Novartis, Sanofi‐Aventis, Takeda Pharma, UCB Pharma.
(© 2021 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
Databáze: MEDLINE
Externí odkaz: